HKSE - Delayed Quote HKD

JW (Cayman) Therapeutics Co. Ltd (2126.HK)

Compare
1.390
-0.010
(-0.71%)
At close: 11:34:08 AM GMT+8
Currency in CNY All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
173,856.000
173,856.000
145,702.000
30,797.000
--
Cost of Revenue
85,637.000
85,637.000
86,946.000
21,752.000
--
Gross Profit
88,219.000
88,219.000
58,756.000
9,045.000
--
Operating Expense
658,611.000
658,611.000
755,078.000
780,203.000
468,455.000
Operating Income
-570,392.000
-570,392.000
-696,322.000
-771,158.000
-468,455.000
Net Non Operating Interest Income Expense
21,611.000
21,611.000
9,748.000
5,604.000
2,671.000
Pretax Income
-767,996.000
-767,996.000
-846,135.000
-702,328.000
-1,663,803.000
Net Income Common Stockholders
-767,996.000
-767,996.000
-846,135.000
-702,328.000
-1,663,803.000
Diluted NI Available to Com Stockholders
-767,996.000
-767,996.000
-846,135.000
-702,328.000
-1,663,803.000
Basic EPS
-1.87
-1.87
-2.06
-1.76
-12.61
Diluted EPS
-1.87
-1.87
-2.06
-1.76
-12.61
Basic Average Shares
411,530.000
411,530.000
410,093.000
399,749.000
131,901.000
Diluted Average Shares
411,530.000
411,530.000
410,093.000
399,749.000
131,901.000
Total Operating Income as Reported
-789,607.000
-789,607.000
-855,883.000
-759,083.000
-440,838.000
Total Expenses
744,248.000
744,248.000
842,024.000
801,955.000
468,455.000
Net Income from Continuing & Discontinued Operation
-767,996.000
-767,996.000
-846,135.000
-702,328.000
-1,663,803.000
Normalized Income
-585,859.000
-585,859.000
-845,967.000
-751,270.000
-1,627,083.000
Interest Income
34,026.000
34,026.000
16,535.000
8,296.000
3,441.000
Interest Expense
12,415.000
12,415.000
6,787.000
2,692.000
770.000
Net Interest Income
21,611.000
21,611.000
9,748.000
5,604.000
2,671.000
EBIT
-755,581.000
-755,581.000
-839,348.000
-699,636.000
-1,663,033.000
EBITDA
-655,747.000
-655,747.000
-752,274.000
-651,411.000
-1,639,443.000
Reconciled Cost of Revenue
85,637.000
85,637.000
86,946.000
21,752.000
--
Reconciled Depreciation
99,834.000
99,834.000
87,074.000
48,225.000
23,590.000
Net Income from Continuing Operation Net Minority Interest
-767,996.000
-767,996.000
-846,135.000
-702,328.000
-1,663,803.000
Total Unusual Items Excluding Goodwill
-182,137.000
-182,137.000
-168.000
48,942.000
-36,720.000
Total Unusual Items
-182,137.000
-182,137.000
-168.000
48,942.000
-36,720.000
Normalized EBITDA
-473,610.000
-473,610.000
-752,106.000
-700,353.000
-1,602,723.000
12/31/2020 - 11/3/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

1GDA.F Zevra Therapeutics, Inc.
7.85
+6.08%
 
471A.F aTyr Pharma, Inc.
3.2800
-4.09%
 
PH4.F CStone Pharmaceuticals
0.2800
-2.10%
 
CVAC.VI CureVac N.V.
3.7560
+4.16%
 
2Q5.BE Enochian BioSciences Inc
0.8000
+3.49%
 
HQ1.MU Oruka Therapeutics Inc. R
11.20
-5.08%
 
GYX.F Futura Medical plc
0.3400
-10.99%
 
ORN.F Oryzon Genomics S.A.
1.4260
-2.73%
 
ANNX.ST Annexin Pharmaceuticals AB (publ)
0.4670
-5.08%
 
25I.F ImmuPharma plc
0.0815
+16.43%